Novo Nordisk to promote drug to treat obesity in United States

COPENHAGEN (Reuters) - Danish pharmaceutical group Novo Nordisk plans to use 500 of its 3,000-strong sales force in the United States to promote its new obesity drug, executive vice president Jakob Riis told Reuters on Monday. The U.S. health regulator has approved a formulation of Novo Nordisk's diabetes drug, liraglutide, for treating obesity, which affects one in three Americans. "We are talking about around 500 people (who) will be focused on launching Saxenda. It is as many as the market can absorb," Riis said. He declined to specify a launch date. ...



via Health News Headlines - Yahoo News http://news.yahoo.com/novo-nordisk-promote-drug-treat-obesity-united-states-144243350--finance.html